Stanley Laman Group Ltd. Purchases New Shares in BioDelivery Sciences International, Inc. (NASDAQ:BDSI)

Stanley Laman Group Ltd. purchased a new stake in shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 349,465 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,366,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its position in shares of BioDelivery Sciences International by 9.3% during the fourth quarter. BlackRock Inc. now owns 8,214,641 shares of the specialty pharmaceutical company’s stock valued at $34,502,000 after purchasing an additional 696,022 shares in the last quarter. HealthInvest Partners AB boosted its position in shares of BioDelivery Sciences International by 27.0% during the first quarter. HealthInvest Partners AB now owns 2,000,000 shares of the specialty pharmaceutical company’s stock valued at $7,820,000 after purchasing an additional 425,000 shares in the last quarter. Nuveen Asset Management LLC boosted its position in shares of BioDelivery Sciences International by 3.8% during the fourth quarter. Nuveen Asset Management LLC now owns 1,858,854 shares of the specialty pharmaceutical company’s stock valued at $7,807,000 after purchasing an additional 68,306 shares in the last quarter. Blair William & Co. IL boosted its position in shares of BioDelivery Sciences International by 4.6% during the fourth quarter. Blair William & Co. IL now owns 1,019,177 shares of the specialty pharmaceutical company’s stock valued at $4,281,000 after purchasing an additional 44,644 shares in the last quarter. Finally, Hillsdale Investment Management Inc. bought a new stake in BioDelivery Sciences International in the first quarter worth $3,430,000. Institutional investors own 67.40% of the company’s stock.

Several equities research analysts have commented on the company. TheStreet raised BioDelivery Sciences International from a “c+” rating to a “b-” rating in a report on Monday, March 1st. HC Wainwright dropped their target price on BioDelivery Sciences International from $7.00 to $5.50 and set a “buy” rating on the stock in a report on Wednesday, March 17th. Finally, Roth Capital dropped their target price on BioDelivery Sciences International from $7.00 to $6.25 and set a “buy” rating on the stock in a report on Thursday, May 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $6.55.

BDSI stock opened at $3.56 on Monday. BioDelivery Sciences International, Inc. has a 1-year low of $3.04 and a 1-year high of $5.45. The business has a fifty day moving average price of $3.50 and a 200-day moving average price of $3.92. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.16 and a quick ratio of 2.80. The stock has a market capitalization of $350.85 million, a P/E ratio of 25.43 and a beta of 0.72.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings data on Thursday, May 6th. The specialty pharmaceutical company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02). The firm had revenue of $41.02 million for the quarter, compared to analysts’ expectations of $40.99 million. BioDelivery Sciences International had a net margin of 10.16% and a return on equity of 25.04%. As a group, analysts anticipate that BioDelivery Sciences International, Inc. will post 0.2 earnings per share for the current year.

In other news, Director Kevin Kotler acquired 150,000 shares of BioDelivery Sciences International stock in a transaction that occurred on Tuesday, May 11th. The stock was bought at an average price of $3.16 per share, for a total transaction of $474,000.00. Following the completion of the transaction, the director now owns 1,098,595 shares in the company, valued at $3,471,560.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.57% of the stock is currently owned by corporate insiders.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies.

See Also: Bar Chart

Want to see what other hedge funds are holding BDSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioDelivery Sciences International, Inc. (NASDAQ:BDSI).

Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.